Published online Apr 26, 2021. doi: 10.12998/wjcc.v9.i12.2703
Peer-review started: November 14, 2020
First decision: December 28, 2020
Revised: January 1, 2021
Accepted: March 11, 2021
Article in press: March 11, 2021
Published online: April 26, 2021
Processing time: 151 Days and 23.8 Hours
A novel coronavirus disease 2019 (COVID-19) is a progressive viral disease that affected people around the world with widespread morbidity and mortality. Patients with COVID-19 infection typically had pulmonary manifestation but can also present with gastrointestinal, cardiac, or neurological system dysfunction. Chest imaging in patients with COVID-19 commonly show bilateral lung involvement with bilateral ground-glass opacity and consolidation. Mediastinal lymphadenopathy can be found due to infectious or non-infectious etiologies. It is commonly found to be associated with malignant diseases, sarcoidosis, and heart failure. Mediastinal lymph node enlargement is not a typical computer tomography of the chest finding of patients with COVID-19 infection. We summarized the literature which suggested or investigated the mediastinal lymph node enlargement in patients with COVID-19 infection. Further studies are needed to better characterize the importance of mediastinal lymphadenopathy in patients with COVID-19 infection.
Core Tip: This reviewed summarized the articles with mediastinal lymphadenopathy evaluation in the patients with a novel coronavirus disease 2019. The content will help understand more regarding current prevalence of mediastinal lymphadenopathy in this population.